Hypermobile joints are a condition characterized by abnormally high joint mobility, which can be the result of both physiological and pathogenetic factors. This condition often manifests itself in children and young people, often leaving habitual and everyday, but can be accompanied by various pains and discomfort. Hypermobility can be part of hypermobility syndrome, also known as Ehlers-Danlos syndrome, and in some cases it can lead to more serious orthopedic and joint problems. This pathology can create significant problems both in adulthood and in old age, which necessitates early diagnosis and an individualized approach to treatment.
History of the disease and interesting historical facts
The term “hypermobile joints” was introduced into scientific practice relatively recently, but references to high joint mobility have existed since the times of ancient Greek medicine. Joint hypermobility was described by many famous doctors of antiquity, such as Hippocrates, who noted that some athletes and acrobats had unusual flexibility. A more modern understanding of hypermobility and its impact on health was developed thanks to the work of the 20th century, when doctors began to associate this condition with certain genetic mutations that contribute to changes in the structure of connective tissue.
Epidemiology
Hypermobile joints tend to manifest and vary in prevalence by geographic region and ethnicity. According to various studies, the rate of hypermobility in the population ranges from 5% to 30%. The condition is more common in women than in men, with the ratio varying from 2:1 to 9:1 depending on the region. Joint hypermobility is even more common in children, which may be due to tissue flexibility and the natural development of the musculoskeletal system.
Genetic predisposition to this disease
Genetic predisposition to joint hypermobility is supported by a number of studies showing a link between mutations in genes responsible for the synthesis of collagen and other connective tissue elements. The most important genes associated with hypermobility include COL5A1, COL5A2, and COL3A1. Mutations in these genes lead to disruption of the collagen structure, which contributes to increased joint mobility. Studying the genetic basis helps to understand the mechanisms of disease development and create new methods for its diagnosis and treatment.
Risk factors for the development of this disease
Risk factors that contribute to the development of joint hypermobility include both physical and chemical ones. These include:
- Genetic predisposition (hereditary factors)
- Lack of physical activity in childhood
- Blood ties among family members who exhibit hypermobility
- Frequent injuries and sprains of joints
- The influence of certain sports disciplines that require high flexibility and stretching (gymnastics, acrobatics)
In addition, chemical factors such as poor diet can affect the condition of connective tissue.
Diagnosis of this disease
Diagnosis of hypermobile joints includes several methods and approaches:
- Main symptoms: increased joint flexibility, frequent dislocations, joint pain after physical exertion.
- Laboratory tests: assessment of inflammatory marker levels and biochemical tests to rule out other causes of joint pain.
- Radiological examinations: X-rays and MRI to assess the condition of the joints and identify structural changes.
- Other types of diagnostics: Ultrasound of joints as a method for assessing the condition of soft tissues.
- Differential diagnosis: exclusion of other forms of joint diseases, such as arthritis, osteochondrosis and various forms of Ehlers-Danlos syndrome.
Treatment
Treatment of joint hypermobility is based on an individual approach and may include various methods:
- General treatment: Prescribe physical therapy to strengthen the muscles that support the joints.
- Pharmacological treatment: use of anti-inflammatory drugs to relieve pain and reduce inflammation.
- Surgical treatment: In complex cases, surgery may be required to correct joints and eliminate dislocations.
- Other types of treatment: use of orthopedic devices (bandages, insoles) to support the joints.
List of medications used to treat this disease
Some of the drugs used in the treatment of hypermobile joints are:
- Ibuprofen
- Naproxen
- Paracetamol
- Celecoxib
- Glucosamine/Chondroitin
Disease monitoring
Monitoring of hypermobile joints includes control stages, since the disease has its own characteristics in the course. The prognosis may vary depending on the severity of symptoms and the presence of concomitant diseases. Complications such as chronic pain syndrome and the risk of joint damage also require careful monitoring.
Age-related features of the disease
Hypermobile joints can manifest themselves differently depending on the age group. In childhood, there is often natural mobility, which usually decreases with age. In older people, hypermobility can worsen, leading to activation of pain syndrome and osteoarthritis.
Questions and Answers
- How do I know if I have hypermobile joints? To do this, it is necessary to undergo an examination by a specialist and assess the mobility of the joints using a special scale.
- Should joint hypermobility be treated? Treatment is necessary if hypermobility causes pain or limitations in daily life.
- Is it possible to play sports with hypermobile joints? It is possible, but it is important to choose activities that do not lead to injury and take into account the characteristics of your joints.
- What movements should you avoid if you have hypermobility? Excessive flexibility and stretching should be avoided, especially in the joints that are most often subject to dislocation.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov emphasizes the importance of prevention and a comprehensive approach to managing joint hypermobility. “It is necessary to engage in physical activity with an emphasis on strengthening the muscles surrounding the joints and avoid movements that can cause injuries. Regular check-ups with a doctor will help monitor the condition of the joints and assess the need for therapy.” The main thing is an individual approach to each patient to avoid exacerbations and maintain quality of life.
